Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology - Report - MDSpire
Advertisement
Two Dana-Farber Hematologists Receive Top Honors From the American Society of Hematology
The American Society of Hematology is recognizing 11 distinguished hematologists with its most prestigious awards and named lectures, honoring transformative contributions that have advanced research, patient care, and education in blood disorders. Two of this year’s honorees are from Dana-Farber Cancer Institute: Benjamin L. Ebert, MD, PhD, and Scott A. Armstrong, MD, PhD.
Clinical Report: Two Dana-Farber Hematologists Receive Top Honors From ASH
Overview
The American Society of Hematology has awarded two Dana-Farber Cancer Institute hematologists for their significant contributions to the field. Dr. Benjamin L. Ebert received the Janet Rowley Basic Science Medal, while Dr. Scott A. Armstrong was honored with the E. Donnall Thomas Lecture and Prize.
Background
Recognition by the American Society of Hematology (ASH) highlights the importance of research and innovation in hematology. Awards such as the Janet Rowley Basic Science Medal and the E. Donnall Thomas Lecture and Prize acknowledge the contributions of researchers in advancing treatment and understanding of blood disorders.
Data Highlights
No numerical or trial data available in the source material.
Key Findings
Dr. Benjamin L. Ebert was awarded the Janet Rowley Basic Science Medal for his contributions to hematology research.
Dr. Ebert's research includes discoveries related to blood cancers and pre-cancers, impacting patient care.
Dr. Scott A. Armstrong received the E. Donnall Thomas Lecture and Prize for his work on leukemia.
Dr. Armstrong's research has led to new therapeutic strategies for various leukemia subtypes.
Both awards will be presented at the 2026 ASH Annual Meeting in New Orleans.
Clinical Implications
The honors received by Dr. Ebert and Dr. Armstrong reflect their contributions to the field of hematology.
Conclusion
The recognition of these two distinguished hematologists highlights their achievements in the field of hematology.
A 59-year-old woman was referred to Nicole Gaulin, MD, a gynecologic oncologist at Roswell Park Comprehensive Cancer Center, after learning she had a BRCA2 mutation linked with both breast cancer in a cousin and colon cancer in her father.
Roswell Park Comprehensive Cancer Center is currently recruiting for a phase 1 clinical trial of the new therapy (NCT07489287), called GB-5267, which was co-developed by Roswell Park and the therapeutics company Generate:Biomedicines.
